Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Report Positive Topline Data from 8 mg Dose of Phase 2 Obesity Trial of GLP-1/GIP Receptor Dual Agonist HRS9531
13. Januar 2025 08:00 ET
|
Kailera Therapeutics, Inc.
Kailera and Hengrui Pharma announced positive topline data from the 8 mg dose of Hengrui’s Phase 2 clinical trial of HRS9531, a GLP-1/GIP dual agonist.
Kailera Therapeutics Appoints Laurie Stelzer as Chief Financial Officer
08. Januar 2025 08:05 ET
|
Kailera Therapeutics, Inc.
Kailera Therapeutics today announced the appointment of Laurie Stelzer as Chief Financial Officer.
Kailera Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
06. Januar 2025 08:15 ET
|
Kailera Therapeutics, Inc.
Ron Renaud, Kailera's President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025.
PMGC Holdings Inc. Following Skincare Subsidiary Sale, Embarks on Bold Growth Strategy
02. Januar 2025 15:55 ET
|
PMGC Holdings Inc.
PMGC Holdings Inc. Following Skincare Subsidiary Sale, Embarks on Bold Growth Strategy
Noom Offers Oral Medications For Weight Loss Starting at $29
12. Dezember 2024 08:03 ET
|
Noom Inc
Noom announced it will expand its Noom Med offerings to include oral medications for weight loss.
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation
09. Dezember 2024 08:00 ET
|
Elevai Labs Inc.
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscl
CORRECTION - Elevai Labs Inc.
14. November 2024 14:35 ET
|
Elevai Labs Inc.
/CORRECTION/ Elevai Labs Inc. Reports Financial Results for the Third Fiscal Quarter of 2024 and Provides Business Update
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
14. November 2024 09:08 ET
|
Elevai Labs Inc.
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity
22. Oktober 2024 09:54 ET
|
Elevai Labs Inc.
Elevai Biosciences Engages Leading CRO to Support Regulatory Planning Efforts and Pre-IND Meeting with the FDA for EL-22 For The Treatment of Obesity
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity
21. Oktober 2024 07:30 ET
|
Elevai Labs Inc.
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Bl